Nasdaq-listed Affimed, a clinical-stage immuno-oncology company, has priced a public offering of 22.5 million of its common shares at US$4.00 per share to raise US$90m – upsized from an initial…
Nasdaq-listed Affimed, a clinical-stage immuno-oncology company, has priced a public offering of 22.5 million of its common shares at US$4.00 per share to raise US$90m – upsized from an initial…
…
Rankings & Reports
M&A
Equity
Healthcare Investing Review
Healthcare Real Assets Report
Resources & Events
Resource Hub
Sector Events
Private Capital Conference
Real Assets Conference